Profile image
Story Views

Last Hour:
Last 24 Hours:

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022: Study Growth Factors, Types and Applications with Market Forecasts

Tuesday, November 15, 2016 1:13
% of readers think this story is Fact. Add your two cents.

Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Gastric Cancer is characterized by the formation of malignant cells in the inner lining of the stomach and is the fifth-most common cancer globally. There are many types of gastric cancer, but adenocarcinoma is the most common type and is diagnosed in 95% of cases. The life expectancy and survival rate for gastric cancer is heavily dependent on the stage of the disease when diagnosed.

Browse more detail information about Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 Report at:

 In Asia-Pacific, most of the incident cases of gastric cancer are diagnosed at the late stage and in patients over the age of 60. As the aged population continues to grow, the prevalence of gastric cancer will increase. This, coupled with increasing early diagnosis and an improved survival rate, will drive revenue growth. Due to its indolent nature, the disease remains one of the most common causes of cancer-related death worldwide. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved targeted therapeutic options.

The current marketed products landscape comprises a wide range of treatment options, including HER2-targeted therapy, angiogenesis inhibitors and new chemotherapies. Nevertheless, significant unmet need remains for products that can treat HER2-negative gastric cancer patients. However, the gastric cancer market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on targeted therapies.

Get a PDF Sample of Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 Research Report at:

In the current market, patients with HER2-positive gastric cancer can be treated with targeted therapies, such as Herceptin, while HER2-negative patients still receive chemotherapy regimens as the first-line treatment. The market will be driven by recently launched products and upcoming targeted therapies during the forecast period. The main restraints will be the low penetration of new targeted therapies, owing to their high price, and constrained healthcare budgets.

Companies Mentioned

  • AstraZeneca
  • Boston Biomedical (subsidiary of Dainippon Sumitomo Pharma)
  • Celgene/Taiho
  • Eli Lilly
  • Gilead Bioscience
  • Jiangsu HengRui Medicine
  • Kuhnil Pharmaceutical/Daiichi Sankyo
  • Merck
  • Ono Pharmaceutical/Bristol-Myers Squibb
  • Roche
  • Taiho

Scope of Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022:

The Asia-Pacific Gastric Cancer Market is forecast to grow at a compound annual growth rate of 11.4% from $1.3 billion in 2015 to $2.7 billion in 2022.

  • How will angiogenesis inhibitors contribute to growth?
  • What effect will the patent expirations of branded therapies have on market value?
  • The pipeline contains a range of molecule types and molecular targets, including those that are well-established in gastric cancer and novel targeted therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline address unmet needs such as a lack of diverse treatment options for gastric cancer patients?
  • What are the most promising first-in-class targets for gastric cancer?
  • Will the current first-in-class targets have broader therapeutic potential across the Asia-Pacific markets?
  • Will the pipeline address unmet needs such as a lack of targeted treatments for HER2-negative gastric cancer patients?
  • Various drivers and barriers will influence the market over the forecast period.
  • What are the barriers that limit the uptake of premium-priced targeted therapeutics in the assessed countries?
  • Which factors are most likely to drive the market in these countries?
  • Licensing deals are the most common form of strategic alliance in gastric cancer, with total deal values ranging from under $10m to over $200m.
  • How do deal frequency and value compare between target families and molecule types?
  • What were the terms and conditions of key licensing deals?


Purchase Report @


Reasons to buy Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022:

This Report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the composition of the gastric cancer market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
  • Analyze the gastric cancer pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating gastric cancer.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict gastric cancer market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the gastric cancer deals landscape by analyzing trends in licensing and co-development deals.

Have any query? Ask our expert @


Detailed TOC of Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Increasing Prevalence and Launch of Targeted Therapies


  • 1 Table of Contents
  • 1 Table of Contents 5
    • List of Tables 8
    • List of Figures 8
  • Introduction 10
    • Disease Introduction 10
    • Epidemiology 10
    • Symptoms 12
    • Etiology 12
    • Pathophysiology 12
      • Helicobacter Pylori 13
      • Oncogenes 13
      • Tumor Suppressor Genes 13
      • Cell Adhesion Molecules and Metastasis-Related Genes 14
      • Cell Cycle Regulators 14
      • Microsatellite and Chromosomal Instability 14
      • Growth Factor and Cytokines 14
    • Diagnosis 15
      • Photofluorography or Barium Study 15
      • Endoscopy 15
      • Imaging Tests 15
      • Endoscopic Ultrasound 16
      • Laparoscopy 16
      • Laboratory Analysis 16
    • Classification and Disease Staging 16
    • 3.1 Overview 21
    • 3.2 HER2-Targeted Therapy 21
    • 3.2.1 Herceptin (trastuzumab) – Roche/Genentech 21
    • 3.3 Angiogenesis Inhibitors 23
    • 3.3.1 Cyramza (ramucirumab) – Eli Lilly 23
    • 3.3.2 Aitan (apatinib) – Jiangsu HengRui Medicine 24
    • 3.4 Newer Chemotherapies 25
    • 3.4.1 TS-1 (tegafur, gimeracil, oteracil) – Taiho 26
    • 3.4.2 Abraxane (nab-paclitaxel) – Celgene/Taiho 26
    • 3.5 Comparative Efficacy and Safety of Marketed Products 27
    • 4 Pipeline Analysis 29
    • 4.1 Overview 29
    • 4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 29
    • 4.3 Pipeline by Molecular Target 31
    • 5.1.3 Failure Rate by Phase and Molecular Target 53
    • 5.2 Clinical Trial Size 55
    • 5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development 55
    • 5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 56
    • 5.3 Clinical Trial Duration 58
    • 5.3.1 Trial Duration by Stage of Development and Molecule Type 58
    • 5.3.2 Trial Duration by Stage of Development and Molecular Target 59
    • 5.4 Summary of Clinical Trial Metrics 60
    • 6 Multi-Scenario Forecast 62
    • 6.1 Geographical Markets 62
    • 6.2 Asia-Pacific Market 62
    • And more…


Get Discount on Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 Research Report at:

About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.

Mr. Ameya Pingaley

Absolute Reports
+1-408 520 9750
Get more market research related news @


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.